Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of HR20031 FDC Tablet in Healthy Subjects
NCT05682495Phase 1Completed
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
- Start
- Jan 2023
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of henagliflozin, retagliptin and metformin in type 2 diabetes mellitus (T2DM) (6 arms), sponsored by Shandong Suncadia Medicine Co., Ltd. Primary endpoints: Maximum Plasma Concentration of SHR3824, Maximum Plasma Concentration of SP2086 and 3 more. Started Jan 2023; status: completed.
02
Drugs
henagliflozinretagliptinmetformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05682495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05682495.